Harlan and Ipsen enter into an agreement to enhance early stage drug development services

April 23, 2012

Harlan and Ipsen enter into an agreement to enhance early stage drug development services

 Harlan Laboratories Contract Research Services (CRS) and Ipsen, a global specialty-driven pharmaceutical company have strengthened their collaboration with a new business agreement.

Under the terms of the agreement, the two companies have entered into a three year programme on the development of early preclinical stage drug candidates with exclusivity in some specific areas.

As a result, Harlan Laboratories has consolidated its standing in the early stage of the drug development process and has established itself as a leader in preclinical drug development.

Harlan Laboratories CRS is one of the world’s leading contract research organisations for the pharmaceutical, agrochemical and chemical industries.  The company offers a wide range of Pharma services with particular expertise in inhalation, infusion, reproductive toxicology, neurotoxicology, immunology, genetic toxicology, oncology and CNS.

The company’s specialised Pharma ADME (Absorption, Distribution, Metabolism and Excretion) department is primarily based at its site in Barcelona and staffed by scientists with in-depth experience and expertise in Pharmacokinetics, in vitro and in vivo ADME and population pharmacokinetics. These capabilities are supported by Harlan’s Swiss facility. This combined expertise makes the company a key player in the pharmaceutical field, providing the full range of studies associated with drug pharmacokinetics and ADME, involving cold and radiolabelled drugs.

“This new agreement with Ipsen is in line with our strategy to satisfy the needs of the pharmaceutical industry in the preclinical arena and underlines our willingness to be close to our customers, helping them to make their drug candidates successful,” comments Dr Ciriaco Maraschiello, Head of Global General Toxicology, Harlan Laboratories CRS. 

“We are delighted to be working with Ipsen and believe this collaboration will offer clients an unrivalled level of expertise and support in the early development of new drug formulations. This is a very important agreement which highlights our commitment to the Pharma sector and reinforces our presence in the drug discovery segment of the drug development process.”



Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.